<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lichenoid drug eruption (drug-induced lichen planus)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lichenoid drug eruption (drug-induced lichen planus)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lichenoid drug eruption (drug-induced lichen planus)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mirjana Ziemer, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H29641535"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lichenoid drug eruption, also called drug-induced lichen planus, is an uncommon, cutaneous adverse effect of several drugs [<a href="#rid1">1-4</a>]. It is characterized by a symmetric eruption of flat-topped, erythematous or violaceous papules resembling lichen planus on the trunk and extremities. The time interval between the initiation of the offending drug and the appearance of the cutaneous lesions varies from several weeks to a year or more and depends upon the class of drug, dose, host reaction, and concurrent medications [<a href="#rid3">3</a>]. Histologic examination reveals lichenoid interface dermatitis [<a href="#rid5">5</a>].</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of lichenoid drug eruptions. Lichen planus and other types of cutaneous adverse reactions to drugs are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/103060.html" rel="external">"Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Dermatologic and mucosal toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H286117"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of lichenoid drug eruption is not known. It occurs more frequently in older adults, most likely related to the increased drug exposure with advancing age, without sex predilection. In small case series, the average age at onset was 44 to 66 years [<a href="#rid6">6-8</a>]. Lichenoid drug eruptions are exceedingly rare in children, with only a few cases reported in the literature [<a href="#rid9">9-11</a>].</p><p class="headingAnchor" id="H29641549"><span class="h1">ETIOLOGY AND PATHOGENESIS</span></p><p class="headingAnchor" id="H29641558"><span class="h2">Immunologic mechanism</span><span class="headingEndMark"> — </span>The pathogenetic mechanism of lichenoid drug reaction is incompletely understood. T cells, keratinocytes, dendritic cells, and endothelial cells, which express activation markers, costimulatory molecules, and adhesion molecules (eg, MHC-class-II molecules, lymphocyte function-associated antigen [LFA] 1, L-selectin, intercellular adhesion molecule [ICAM] 1) are thought to be involved in the inflammatory reaction that ultimately leads to the apoptosis of basal keratinocytes [<a href="#rid12">12</a>].</p><p>Both CD4 and CD8 T cells are found at the dermoepidermal junction and within the epidermis. As in lichen planus, a persistent activation of CD8 autocytotoxic T lymphocytes against epidermal cells may be the crucial pathophysiologic factor [<a href="#rid13">13</a>]. Activated CD8 T cells induce the apoptosis of basal epidermal keratinocytes mainly through the perforin/granzyme B pathway [<a href="#rid14">14,15</a>]. These cells also produce type I and type II cytokines, such as interferon (IFN)-gamma and interleukin (IL) 5 [<a href="#rid14">14-16</a>]. IFN-gamma induces the expression of MHC-class-II molecules on keratinocytes and facilitates drug binding and presentation to CD4 T cells [<a href="#rid12">12</a>]. The stereotypical appearance of lichenoid drug reaction during immune checkpoint inhibitor therapies may underline the importance of T cell-triggered cytotoxicity [<a href="#rid17">17,18</a>].</p><p>Plasmacytoid dendritic cells are also thought to be involved in the early phase of lichenoid tissue reaction. They produce large amounts of type I IFN, such as IFN-alpha, which mediate the activation of IFN-gamma-secreting cytotoxic T cells directly or through the maturation of myeloid dendritic cells [<a href="#rid19">19</a>]. Tumor necrosis factor (TNF)-alpha and other inflammatory cytokines and chemokines are responsible for the amplification of the inflammatory response [<a href="#rid20">20-23</a>].</p><p class="headingAnchor" id="H29641565"><span class="h2">Medications</span><span class="headingEndMark"> — </span>Cutaneous lichenoid eruptions have been associated with a broad variety of drugs  (<a class="graphic graphic_table graphicRef83762" href="/z/d/graphic/83762.html" rel="external">table 1</a>), most frequently [<a href="#rid2">2-4,6,9,17,18,24-37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin-converting enzyme (ACE) inhibitors</p><p class="bulletIndent1"><span class="glyph">●</span>Thiazide diuretics</p><p class="bulletIndent1"><span class="glyph">●</span>Antimalarials</p><p class="bulletIndent1"><span class="glyph">●</span>Beta blockers</p><p class="bulletIndent1"><span class="glyph">●</span>Gold salts</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">Penicillamine</a></p><p class="bulletIndent1"><span class="glyph">●</span>Immune checkpoint inhibitors</p><p class="bulletIndent1"><span class="glyph">●</span>Tyrosine kinase inhibitors (eg, <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> mesylate) </p><p class="bulletIndent1"><span class="glyph">●</span>TNF-alpha antagonists (eg, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>)</p><p></p><p>Lichenoid eruptions involving the oral mucosa have been associated with [<a href="#rid6">6,9,17,18,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">Allopurinol</a></p><p class="bulletIndent1"><span class="glyph">●</span>ACE inhibitors</p><p class="bulletIndent1"><span class="glyph">●</span>Gold salts</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">Ketoconazole</a> </p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal anti-inflammatory drugs (NSAIDs)</p><p class="bulletIndent1"><span class="glyph">●</span>Anticonvulsants</p><p class="bulletIndent1"><span class="glyph">●</span>Antiretrovirals</p><p class="bulletIndent1"><span class="glyph">●</span>Immune checkpoint inhibitors</p><p></p><p>In a systematic review of 49 reports (67 patients) of lichenoid drug eruptions associated with the use of biologic therapy, the most frequently implicated biologics were TNF-alpha inhibitors (78 percent), IL-1 inhibitors (9 percent), and IL-17A inhibitors (4.5 percent) [<a href="#rid38">38</a>]. The median time between biologic administration and lichenoid eruption was three months. Dupilumab-induced lichenoid and/or granulomatous-lichenoid eruptions in patients with atopic dermatitis may be explained by T helper (Th) 2 inhibition by <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> upregulation of Th1 pathways, which enhances Th1/Th17-dominated responses [<a href="#rid39">39-41</a>].</p><p>A papular, lichenoid eruption with histopathologic features of lichenoid interface dermatitis is one of the most common skin reactions reported in patients with cancer treated with antagonist antibodies to immunologic checkpoints (eg, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>), programmed cell death ligand 1 (PD-L1; eg, <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>, <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a>), or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>) [<a href="#rid17">17,24,33,42-46</a>]. (See  <a class="medical medical_review" href="/z/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p>It is assumed that programmed cell death protein 1 (PD-1), PD-L1, or CTLA-4 inhibition leads to impaired T cell homeostasis in the skin, thus facilitating such cytotoxic inflammatory reactions. In a study comparing the RNA expression profile in affected skin from five patients with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and five individuals with skin reactions while on anti-PD-1 treatment, both SJS/TEN and anti-PD-1-induced eruptions were associated with expression of PI3 (elafin), GZMB (granzyme B), and CXCL9-11 (a group of chemokines involved in T cell activation) [<a href="#rid42">42</a>]. Unlike SJS/TEN, however, skin reactions from anti-PD-1 therapy showed increased expression of CCL27, granulysin, FAS ligand, and perforin. These findings were unusual and contradicted previously published data.</p><p>Moreover, a lichen planus-like eruption has been reported following BNT162b2 (Pfizer-BioNTech) [<a href="#rid47">47-51</a>], mRNA-1273 (Moderna) [<a href="#rid49">49</a>], and ChAdOx1 nCoV-19/AZD1222 (University of Oxford-AstraZeneca) [<a href="#rid49">49,52,53</a>] coronavirus disease 2019 (COVID-19) vaccine administration. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p>Because lichen planus can be associated with several viral infections (eg, hepatitis B and C virus or varicella-zoster virus) and has also been reported following other vaccinations (especially hepatitis B virus, influenza, and herpes zoster vaccines), the differentiation from a lichenoid drug eruption is rather impossible [<a href="#rid54">54</a>].</p><p>There are several reports of lichenoid eruption associated with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> and <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> [<a href="#rid10">10,55-58</a>].</p><p class="headingAnchor" id="H29641579"><span class="h2">Contribution of ultraviolet irradiation</span><span class="headingEndMark"> — </span>Photosensitive lichenoid eruptions have been reported in patients taking a variety of drugs, in particular [<a href="#rid6">6,59-61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Thiazide diuretics</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">Diltiazem</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">Quinidine</a></p><p class="bulletIndent1"><span class="glyph">●</span>Tetracyclines</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">Chlorpromazine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a></p><p></p><p>The action spectrum for these drugs appears to be in the ultraviolet B (UVB) wavelength range (290 to 320 nm) [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H29641593"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H286780918"><span class="h2">Latency</span><span class="headingEndMark"> — </span>The latency period between drug initiation and appearance of the eruption varies from months to a year or more and depends upon the type of drug, dose, host reaction, previous exposure to the drug, and concurrent medications [<a href="#rid3">3</a>]. A latency period of two months to three years has been reported for <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, three to six months for angiotensin-converting enzyme (ACE) inhibitors, and four to six weeks for quinacrine [<a href="#rid30">30-32</a>].</p><p class="headingAnchor" id="H29641602"><span class="h2">Skin lesions</span><span class="headingEndMark"> — </span>Lichenoid drug eruption is characterized by a symmetric eruption of flat-topped, erythematous or violaceous papules, often grouped and confluent, on the trunk and extremities  (<a class="graphic graphic_picture graphicRef126318 graphicRef83767 graphicRef83768" href="/z/d/graphic/126318.html" rel="external">picture 1A-C</a>). Lesions closely resemble those seen in lichen planus  (<a class="graphic graphic_picture graphicRef76383 graphicRef50632" href="/z/d/graphic/76383.html" rel="external">picture 2A-B</a>), although in lichenoid drug eruption the individual lesions are less monomorphic and may have eczematous or psoriasiform morphology with marked desquamation [<a href="#rid63">63</a>]. In patients with darkly pigmented skin, lesions may be rather brown or hyperpigmented [<a href="#rid64">64</a>]. Wickham striae  (<a class="graphic graphic_picture graphicRef61523" href="/z/d/graphic/61523.html" rel="external">picture 3</a>), consisting of fine, white lacelike patterns highly characteristic of lichen planus, are usually absent, but their presence does not exclude a drug-related etiology [<a href="#rid63">63</a>].</p><p>The eruption can be localized or generalized, with a fairly symmetrical distribution. In some patients, the lesions are localized to the photoexposed areas and exhibit photoaggravation. In contrast to lichen planus, the lesions of lichenoid drug eruption are distributed on the extensor aspects of the extremities and dorsal aspects of the hands  (<a class="graphic graphic_picture graphicRef76383 graphicRef83769 graphicRef59258" href="/z/d/graphic/76383.html" rel="external">picture 2A, 2C-D</a> and <a class="graphic graphic_picture graphicRef126318" href="/z/d/graphic/126318.html" rel="external">picture 1A</a>) [<a href="#rid26">26</a>]. Nails are usually spared. (See <a class="local">'Lichen planus'</a> below.)</p><p>Checkpoint inhibitors may induce severe bullous forms of lichenoid drug eruption with frequent mucosal involvement  (<a class="graphic graphic_picture graphicRef126976" href="/z/d/graphic/126976.html" rel="external">picture 4</a>). Some patients present with isolated lichenoid mucositis [<a href="#rid8">8</a>]. These severe forms of lichenoid drug eruption need to be differentiated from other severe cutaneous adverse eruptions, such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Compared with SJS/TEN, the clinical course of these bullous lichenoid reactions is more protracted, the mucosal involvement is mild or absent, and the overall clinical outcome is better than for SJS/TEN. (See <a class="local">'Stevens-Johnson syndrome/toxic epidermal necrolysis'</a> below and  <a class="medical medical_review" href="/z/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p>Pruritus is frequent, although some patients are completely asymptomatic.</p><p class="headingAnchor" id="H29641609"><span class="h2">Oral lesions</span><span class="headingEndMark"> — </span>Oral lichenoid drug eruptions are rare. The lesions are identical to those of oral lichen planus and may have an erosive or reticular morphology  (<a class="graphic graphic_picture graphicRef83774" href="/z/d/graphic/83774.html" rel="external">picture 5</a>). Erosive lesions are associated with pain, burning, and irritation. Reticular forms are usually asymptomatic. Oral lichenoid drug eruptions have been associated with several drugs, including <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, ACE inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and antiretrovirals [<a href="#rid6">6,9</a>]. (See <a class="local">'Medications'</a> above.)</p><p class="headingAnchor" id="H71523368"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>The eruption resolves in weeks to months after the discontinuation of the offending drug, leaving postinflammatory hyperpigmentation  (<a class="graphic graphic_picture graphicRef83771" href="/z/d/graphic/83771.html" rel="external">picture 6</a>). Occasionally, the eruption disappears or recurs intermittently despite continuation of treatment [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H29641623"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H29641632"><span class="h2">Histopathologic findings</span><span class="headingEndMark"> — </span>Histologically, lichenoid drug eruption is an interface dermatitis. Lichenoid interface dermatitis is a nonspecific reaction pattern occurring in idiopathic lichen planus and other lichenoid eruptions (eg, lichenoid purpura, cutaneous graft-versus-host disease, pityriasis lichenoides chronica, discoid lupus erythematosus, fixed drug eruption) [<a href="#rid5">5</a>]. Lichenoid interface dermatitis also may be found in some cases of maculopapular drug reactions.</p><p>Major pathologic findings seen in both lichenoid drug eruption and lichen planus include:</p><p class="bulletIndent1"><span class="glyph">●</span>Damage of basal epidermal keratinocytes with multiple apoptotic cells (colloid or Civatte bodies)</p><p class="bulletIndent1"><span class="glyph">●</span>A band-like, lymphocytic infiltrate in the papillary dermis that obscures the dermoepidermal junction</p><p class="bulletIndent1"><span class="glyph">●</span>Pigmentary incontinence with dermal melanophages</p><p></p><p>Findings that are more typical of lichenoid drug eruption than lichen planus include  (<a class="graphic graphic_table graphicRef83936" href="/z/d/graphic/83936.html" rel="external">table 2</a> and <a class="graphic graphic_picture graphicRef83937" href="/z/d/graphic/83937.html" rel="external">picture 7</a>) [<a href="#rid8">8,26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Focal parakeratosis</p><p class="bulletIndent1"><span class="glyph">●</span>Focal interruption of the granular layer</p><p class="bulletIndent1"><span class="glyph">●</span>Cytoid bodies in the cornified and granular layers</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of eosinophils</p><p class="bulletIndent1"><span class="glyph">●</span>A higher number of necrotic keratinocytes, sometimes in clusters, as well as plasma cells and eosinophils</p><p class="bulletIndent1"><span class="glyph">●</span>Exocytosis of lymphoid cells into the upper epidermis</p><p class="bulletIndent1"><span class="glyph">●</span>Deeper, perivascular infiltrate</p><p></p><p>These features are seen more often in non-photodistributed lesions. Photodistributed lesions are usually indistinguishable from idiopathic lichen planus.</p><p class="headingAnchor" id="H29641639"><span class="h2">Direct immunofluorescence</span><span class="headingEndMark"> — </span>Direct immunofluorescence shows globular deposits of immunoglobulin M (IgM), and occasionally immunoglobulin G (IgG) and immunoglobulin A (IgA), at the dermoepidermal junction and in the lower epidermis. Shaggy deposition of fibrinogen at the dermoepidermal junction is also seen. As in lichen planus, marked cytoid body staining may be present in most cases [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H29641646"><span class="h2">Immunohistochemical studies</span><span class="headingEndMark"> — </span>Immunohistochemical studies show that the majority of the cells in the infiltrate at the dermoepidermal interface are CD4 and autoreactive CD8 effector T cells. In contrast to idiopathic lichen planus, in lichenoid drug reaction a correlation has been found between the number of T cells and CD8<sup>+</sup> cells and between the number of granzyme B<sup>+</sup> cells and necrotic keratinocytes [<a href="#rid8">8</a>]. Immunohistochemical staining is not routinely performed for the diagnosis of lichenoid skin eruption.</p><p class="headingAnchor" id="H29641653"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of lichenoid drug eruption is based upon a combination of the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Symmetric eruption of flat-topped, erythematous or violaceous papules, often grouped and confluent, resembling lichen planus on the trunk and extremities  (<a class="graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769" href="/z/d/graphic/83767.html" rel="external">picture 1B-C, 2C</a>). (See <a class="local">'Skin lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of a skin biopsy</strong> – Histologic findings of interface dermatitis with a band-like lymphocytic infiltrate and other histopathologic features more characteristic of lichenoid drug eruption  (<a class="graphic graphic_picture graphicRef83937" href="/z/d/graphic/83937.html" rel="external">picture 7</a>). (See <a class="local">'Histopathologic findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication history</strong> – Evidence of temporal relationship between drug intake and development of skin lesions. The assessment of a temporal relationship between drug intake and onset of the eruption may be difficult because of the wide variability in the latency time, particularly in patients on multiple medications. (See <a class="local">'Latency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course</strong> – Resolution upon drug withdrawal and recurrence upon rechallenge.</p><p></p><p>Patch testing with the patient's drugs has been used to try to determine the offending agent in patients with various types of cutaneous drug reactions and in patients with oral lichen planus [<a href="#rid68">68-70</a>]. However, patch testing is not routinely performed in patients with suspected lichenoid drug eruptions because false negative results are frequent. In small observational studies only 30 to 50 percent of patients with cutaneous drug reactions had positive or clinically relevant patch tests [<a href="#rid68">68-70</a>].</p><p class="headingAnchor" id="H29641676"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H3364460222"><span class="h2">Lichen planus</span><span class="headingEndMark"> — </span>The cutaneous lesions of lichen planus are shiny, flat, polygonal, violaceous papules  (<a class="graphic graphic_picture graphicRef70518 graphicRef58361 graphicRef50632" href="/z/d/graphic/70518.html" rel="external">picture 2B, 2E-F</a>); the morphology is similar to that of lichenoid drug eruption. However, in lichen planus, fine, white lacelike patterns known as Wickham striae are present over the surface of many papules  (<a class="graphic graphic_picture graphicRef61523" href="/z/d/graphic/61523.html" rel="external">picture 3</a>). Moreover, the lesions of idiopathic lichen planus are typically distributed symmetrically over the extremities and tend to involve the flexural areas of wrists, arms, and legs  (<a class="graphic graphic_picture graphicRef76383" href="/z/d/graphic/76383.html" rel="external">picture 2A</a>), whereas in lichenoid drug eruption the lesions typically occur on the trunk and extensor surfaces. Oral involvement is common in lichen planus and less so in lichenoid drug eruption. The histopathologic differential diagnosis of lichen planus and lichenoid drug eruption is summarized in the table  (<a class="graphic graphic_table graphicRef83936" href="/z/d/graphic/83936.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a>.)</p><p class="headingAnchor" id="H3424284005"><span class="h2">Stevens-Johnson syndrome/toxic epidermal necrolysis</span><span class="headingEndMark"> — </span>Severe bullous lichenoid drug eruption associated with checkpoint inhibitors is rare and needs to be differentiated from Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Key clinical aspects that distinguish a lichenoid eruption from SJS/TEN include:</p><p class="bulletIndent1"><span class="glyph">●</span>A shorter latency between drug intake and onset of skin lesions (four days to up to four weeks) in SJS/TEN compared with lichenoid eruption.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protracted, rather than acute, clinical course of lichenoid eruptions, with slow development of bullous lesions  (<a class="graphic graphic_picture graphicRef126976" href="/z/d/graphic/126976.html" rel="external">picture 4</a>) over time in some patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild or absent mucosal involvement in lichenoid eruptions compared with the almost universal mucosal involvement in SJS/TEN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical outcome of lichenoid drug eruption is generally favorable.</p><p></p><p>The histology of both lichenoid drug eruptions and SJS/TEN is characterized by necrotic keratinocytes and subepidermal cleft formation. However, the more prominent lymphocytic infiltrate, along with jagged acanthosis (often with parakeratosis), is suggestive of lichenoid drug eruption.</p><p>A 2019 critical analysis of published cases of SJS/TEN and TEN-like reactions associated with immune checkpoint inhibitor therapy (n = 14) showed that many likely represented bullous lichenoid drug eruptions; isolated, erosive lichenoid mucositis; or bullous dermatitis in previously irradiated skin (radiation recall dermatitis), with only a few of these cases being genuine SJS/TEN [<a href="#rid18">18</a>]. An analysis of 4150 severe, cutaneous adverse reactions reported to the German registry between January 2003 and February 2019 in the context of immuno-oncologic medication confirmed only one case of TEN induced by <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>. Several reported bullous cases represented bullous lichenoid drug reactions to pembrolizumab, <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">obinutuzumab</a>, and <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3836019052"><span class="h2">Lupus erythematosus</span><span class="headingEndMark"> — </span>The macular-papular exanthema in lichenoid drug eruption, especially if accentuated in photoexposed areas, has similarities with lupus erythematosus. On histology, a lichenoid interface dermatitis may be seen in some cases of chronic cutaneous lupus erythematosus. In contrast to lichenoid drug eruption, lesions of lupus erythematosus show a moderately dense perivascular and periappendageal lymphocytic infiltrate in the papillary and reticular dermis, with abundant mucin deposits in the latter. There is focal or continuous epidermal thinning, smudged appearance of the dermoepidermal junction with vacuolar degeneration of basal cells, individual necrotic keratinocytes, and a thickened basal membrane zone. Direct immunofluorescence reveals a band-like deposition of IgG and IgM along the basement membrane zone in most cases. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H3544077262"><span class="h2">Lichenoid granulomatous dermatitis</span><span class="headingEndMark"> — </span>Lichenoid granulomatous dermatitis is a histopathologic reaction pattern with vacuolar alteration of the basal layer with necrotic keratinocytes and a chronic, inflammatory infiltrate consisting of lymphocytes, eosinophils, plasma cells, and macrophages forming variable types of granulomas. In more than one-third of the cases, the most common clinical correlates are drug eruptions [<a href="#rid71">71</a>].</p><p>Other specific diagnoses that share this histopathologic pattern are lichenoid keratosis, tattoo reactions, postherpetic dermatitis, scabies or postscabietic dermatitis, pigmented purpuric dermatosis, and lichen striatus. Dermal eosinophils and psoriasiform epidermal changes are more often associated with drug eruptions, perineural and perifollicular inflammation are more often associated with tattoo reaction and postherpetic dermatitis, and red blood cell extravasation is more often associated with pigmented purpuric dermatosis [<a href="#rid71">71</a>].</p><p>A special and rare subtype is giant cell lichenoid dermatitis, a rare condition considered an unusual variant of lichenoid drug eruption or a manifestation of sarcoidosis [<a href="#rid72">72</a>]. Histopathologic findings include multinucleated giant cells.</p><p class="headingAnchor" id="H2535060764"><span class="h2">Keratosis lichenoides chronica</span><span class="headingEndMark"> — </span>Keratosis lichenoides chronica, also called Nekam's disease, is a rare disorder characterized by violaceous, tiny papules centered on hair infundibula and sweat ducts and arranged in a linear and reticulate pattern  (<a class="graphic graphic_picture graphicRef126319" href="/z/d/graphic/126319.html" rel="external">picture 8</a>) [<a href="#rid73">73,74</a>]. Histologically, there is a lichenoid infiltrate with focal epidermal acanthosis and atrophy.</p><p class="headingAnchor" id="H29641683"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H38715886"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Lichenoid drug eruptions generally resolve spontaneously a few weeks to a few months after the discontinuation of the offending drug [<a href="#rid6">6,75</a>]. However, treatment may be warranted in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who cannot discontinue the offending drug</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged disease (ie, persistent lesions several months after discontinuation of the drug)</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive disease (eg, involving the trunk and extremities)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms (eg, pruritus)</p><p></p><p class="headingAnchor" id="H64668815"><span class="h2">Cutaneous eruption</span><span class="headingEndMark"> — </span>Treatment options include topical or systemic corticosteroids and oral retinoids.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with symptomatic disease involving a limited skin area (eg, the extremities), we suggest topical corticosteroids rather than oral corticosteroids. We generally use a superpotent topical corticosteroid (eg, <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05%  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 3</a>)) ointment or cream twice daily for two to four weeks. Mid-potency corticosteroids, such as <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> furoate 0.1% ointment or cream, can be used for facial lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with extensive, symptomatic disease, we suggest oral corticosteroids rather than oral retinoids. In adult patients, we generally use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> 25 to 35 mg per day for 6 to 12 weeks is an alternative for patients in whom systemic corticosteroids are contraindicated.</p><p></p><p>The efficacy of topical corticosteroids, systemic corticosteroids, and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> for lichenoid drug eruption has not been evaluated in randomized trials. Their use is based upon clinical experience and limited evidence of efficacy from a few small clinical studies in patients with idiopathic lichen planus [<a href="#rid76">76-78</a>]. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H64668843"><span class="h2">Oral eruption</span><span class="headingEndMark"> — </span>The reticular form of oral lichenoid drug eruption is generally asymptomatic and does not require treatment. Topical or oral corticosteroids are used for the treatment of the erosive form to reduce pain and discomfort and hasten healing.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with oral, erosive lichenoid drug eruption, we suggest topical corticosteroids as first-line treatment. We typically use a superpotent topical corticosteroid (eg, <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05% ointment) two or three times per day for four to eight weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with oral, erosive lichenoid drug eruption that does not respond to topical corticosteroids, we suggest oral corticosteroids. In adult patients, we generally use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks.</p><p></p><p>The efficacy of topical and oral corticosteroids for the treatment of oral, erosive lichenoid drug eruption has not been evaluated in randomized trials. Their use is based upon clinical experience and limited evidence of efficacy from randomized trials in idiopathic oral lichen planus [<a href="#rid79">79,80</a>]. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a> and  <a class="medical medical_review" href="/z/d/html/86851.html" rel="external">"Oral lichen planus: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H2859688737"><span class="h1">RECHALLENGE</span><span class="headingEndMark"> — </span>Re-exposure, in general, is contraindicated but possible in individual patients after thorough risk-benefit evaluation if the provoking drug is of irreplaceable importance [<a href="#rid45">45,81</a>].</p><p class="headingAnchor" id="H33247710"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">"Society guideline links: Drug allergy and hypersensitivity"</a>.)</p><p class="headingAnchor" id="H29641690"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Lichenoid drug eruption, also called drug-induced lichen planus, is an uncommon, cutaneous adverse effect of several drugs, characterized by a symmetric, papular eruption resembling lichen planus on the trunk and extremities. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The drugs most frequently reported are angiotensin-converting enzyme (ACE) inhibitors, thiazide diuretics, antimalarials, beta blockers, and checkpoint inhibitors  (<a class="graphic graphic_table graphicRef83762" href="/z/d/graphic/83762.html" rel="external">table 1</a>). The latency period between drug initiation and the appearance of the eruption varies from several weeks to a year or more. (See <a class="local">'Medications'</a> above and <a class="local">'Latency'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Lichenoid drug eruption manifests with a symmetric eruption of erythematous or violaceous, flat-topped, polygonal papules, often grouped and confluent. They have eczematous or psoriasiform morphology with marked desquamation. The eruption involves the trunk and predominantly extensor aspects of the extremities  (<a class="graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769 graphicRef59258" href="/z/d/graphic/83767.html" rel="external">picture 1B-C, 2C-D</a>). Severe bullous lichenoid reactions that mimic Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have been associated with checkpoint inhibitors  (<a class="graphic graphic_picture graphicRef126976" href="/z/d/graphic/126976.html" rel="external">picture 4</a>). (See <a class="local">'Skin lesions'</a> above and <a class="local">'Stevens-Johnson syndrome/toxic epidermal necrolysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of lichenoid drug eruption is based upon a combination of the following (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical findings of a symmetric eruption of flat-topped, erythematous or violaceous papules resembling lichen planus on the trunk and extremities  (<a class="graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769" href="/z/d/graphic/83767.html" rel="external">picture 1B-C, 2C</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic findings of interface dermatitis with a band-like, lymphocytic infiltrate and necrotic keratinocytes  (<a class="graphic graphic_picture graphicRef83937" href="/z/d/graphic/83937.html" rel="external">picture 7</a>) (see <a class="local">'Histopathologic findings'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Temporal relationship between drug intake and development of skin lesions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Resolution upon drug withdrawal and recurrence upon rechallenge</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course</strong> – Lichenoid drug eruptions generally resolve spontaneously a few weeks to a few months after the discontinuation of the offending drug. Treatment may be warranted in patients who cannot discontinue the offending drug or have symptomatic or extensive disease. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limited disease</strong> – For patients with symptomatic disease involving a limited skin area (eg, the extremities), we suggest topical corticosteroids rather than oral corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally use a superpotent topical corticosteroid (eg, <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05%  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 3</a>)) ointment or cream twice daily for two to four weeks. Less potent topical corticosteroids, such as <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> furoate 0.1% ointment or cream, can be used for facial lesions. (See <a class="local">'Cutaneous eruption'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extensive/symptomatic disease</strong> – For patients with extensive, symptomatic disease, we suggest oral corticosteroids rather than oral retinoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> 25 to 35 mg per day for 6 to 12 weeks is an alternative for patients in whom systemic corticosteroids are contraindicated. (See <a class="local">'Cutaneous eruption'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral, erosive lesions</strong> – For patients with oral, erosive lichenoid drug eruption, we suggest topical corticosteroids rather than oral corticosteroids as first-line treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate 0.05% ointment two or three times per day for four to eight weeks. (See <a class="local">'Oral eruption'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory, oral lesions</strong> – For patients with oral, erosive lichenoid drug eruption that does not respond to topical corticosteroids, we suggest oral corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. (See <a class="local">'Oral eruption'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fox GN, Harrell CC, Mehregan DR. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature. Cutis 2005; 76:41.</a></li><li><a class="nounderline abstract_t">Antiga E, Melani L, Cardinali C, et al. A case of lichenoid drug eruption associated with sildenafil citratus. J Dermatol 2005; 32:972.</a></li><li><a class="nounderline abstract_t">Brauer J, Votava HJ, Meehan S, Soter NA. Lichenoid drug eruption. Dermatol Online J 2009; 15:13.</a></li><li><a class="nounderline abstract_t">Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104.</a></li><li><a class="nounderline abstract_t">Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129:1088.</a></li><li><a class="nounderline abstract_t">Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29:249.</a></li><li><a class="nounderline abstract_t">West AJ, Berger TG, LeBoit PE. A comparative histopathologic study of photodistributed and nonphotodistributed lichenoid drug eruptions. J Am Acad Dermatol 1990; 23:689.</a></li><li><a class="nounderline abstract_t">Lage D, Juliano PB, Metze K, et al. Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol 2012; 51:1199.</a></li><li><a class="nounderline abstract_t">Woo V, Bonks J, Borukhova L, Zegarelli D. Oral lichenoid drug eruption: a report of a pediatric case and review of the literature. Pediatr Dermatol 2009; 26:458.</a></li><li><a class="nounderline abstract_t">May C, Fleckman P, Brandling-Bennett HA, et al. Lichenoid Drug Eruption with Prominent Nail Changes Due to Leflunomide in a 12-Year-Old Child. Pediatr Dermatol 2017; 34:e225.</a></li><li><a class="nounderline abstract_t">Romanelli M, Rhodes A. Guanfacine-induced lichenoid drug eruption in a child with autism and attention deficit hyperactivity disorder. Pediatr Dermatol 2014; 31:614.</a></li><li><a class="nounderline abstract_t">Yawalkar N, Pichler WJ. [Mechanisms of cutaneous drug reactions]. J Dtsch Dermatol Ges 2004; 2:1013.</a></li><li><a class="nounderline abstract_t">Sugerman PB, Satterwhite K, Bigby M. Autocytotoxic T-cell clones in lichen planus. Br J Dermatol 2000; 142:449.</a></li><li><a class="nounderline abstract_t">Yawalkar N, Pichler WJ. Immunohistology of drug-induced exanthema: clues to pathogenesis. Curr Opin Allergy Clin Immunol 2001; 1:299.</a></li><li><a class="nounderline abstract_t">Yawalkar N, Egli F, Hari Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30:847.</a></li><li><a class="nounderline abstract_t">Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106:1171.</a></li><li><a class="nounderline abstract_t">Kratzsch D, Simon JC, Ziemer M. Lichen planus-like drug eruption on anti-PD-1 therapy. J Dtsch Dermatol Ges 2017; 15:1238.</a></li><li><a class="nounderline abstract_t">Reschke R, Mockenhaupt M, Simon JC, Ziemer M. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges 2019; 17:942.</a></li><li><a class="nounderline abstract_t">Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol 2009; 129:315.</a></li><li><a class="nounderline abstract_t">Wenzel J, Scheler M, Proelss J, et al. Type I interferon-associated cytotoxic inflammation in lichen planus. J Cutan Pathol 2006; 33:672.</a></li><li><a class="nounderline abstract_t">Erdem MT, Gulec AI, Kiziltunc A, et al. Increased serum levels of tumor necrosis factor alpha in lichen planus. Dermatology 2003; 207:367.</a></li><li><a class="nounderline abstract_t">Akasu R, From L, Kahn HJ. Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus. Am J Dermatopathol 1993; 15:217.</a></li><li><a class="nounderline abstract_t">Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol 2007; 143:233.</a></li><li><a class="nounderline abstract_t">Maul JT, Guillet C, Oschmann A, et al. Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications. J Eur Acad Dermatol Venereol 2023; 37:965.</a></li><li><a class="nounderline abstract_t">Teraki Y, Shiohara T. Spontaneous tolerance to terbinafine-induced lichenoid drug eruption. Dermatology 2004; 208:81.</a></li><li><a class="nounderline abstract_t">Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 1989; 179:10.</a></li><li><a class="nounderline abstract_t">Bong JL, Lucke TW, Douglas WS. Lichenoid drug eruption with proton pump inhibitors. BMJ 2000; 320:283.</a></li><li><a class="nounderline abstract_t">De Simone C, Caldarola G, D'Agostino M, et al. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008; 22:626.</a></li><li><a class="nounderline abstract_t">Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138:1258.</a></li><li><a class="nounderline abstract_t">Powell FC, Rogers RS 3rd, Dickson ER. Primary biliary cirrhosis and lichen planus. J Am Acad Dermatol 1983; 9:540.</a></li><li><a class="nounderline abstract_t">Rotstein E, Rotstein H. Drug eruptions with lichenoid histology produced by captopril. Australas J Dermatol 1989; 30:9.</a></li><li><a class="nounderline abstract_t">Bauer F. Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential: a review. J Am Acad Dermatol 1981; 4:239.</a></li><li><a class="nounderline abstract_t">Shi VJ, Rodic N, Gettinger S, et al. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatol 2016; 152:1128.</a></li><li><a class="nounderline abstract_t">Wahiduzzaman M, Pubalan M. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review. Dermatol Online J 2008; 14:14.</a></li><li><a class="nounderline abstract_t">Inoue A, Sawada Y, Yamaguchi T, et al. Lichenoid drug eruption caused by adalimumab: a case report and literature review. Eur J Dermatol 2017; 27:69.</a></li><li><a class="nounderline abstract_t">Kunadia A, Shulman K, Sami N. Certolizumab-induced lichenoid eruption in a patient with rheumatoid arthritis. BMJ Case Rep 2021; 14.</a></li><li><a class="nounderline abstract_t">Almheirat Y, Bouabdalla S, Daflaoui H, et al. Imatinib-induced lichen planus and lichenoid drug eruption: A report of three cases. J Cutan Pathol 2023; 50:415.</a></li><li><a class="nounderline abstract_t">Kim PJ, Sachdeva M, Mufti A, et al. Lichenoid Drug Eruptions Associated With the Use of Biologic Therapy: A Systematic Review. J Cutan Med Surg 2022; 26:521.</a></li><li><a class="nounderline abstract_t">Rehan Z, Pratt MD, Teo I, et al. Lichenoid-granulomatous drug reactions to dupilumab: A report of 2 cases. JAAD Case Rep 2023; 33:13.</a></li><li><a class="nounderline abstract_t">Kim TE, Shin MK. De novo case of lichenoid eruption following dupilumab treatment. JAAD Case Rep 2021; 13:71.</a></li><li><a class="nounderline abstract_t">Derbyshire M, Beatty C, Marks K, Kazlouskaya V. Lichenoid eruption during treatment of atopic dermatitis with dupilumab. Int J Dermatol 2023; 62:1202.</a></li><li><a class="nounderline abstract_t">Goldinger SM, Stieger P, Meier B, et al. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Clin Cancer Res 2016; 22:4023.</a></li><li><a class="nounderline abstract_t">Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 2016; 43:339.</a></li><li><a class="nounderline abstract_t">Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60:190.</a></li><li><a class="nounderline abstract_t">Ziemer M, Fries V, Paulmann M, Mockenhaupt M. Epidermal necrolysis in the context of immuno-oncologic medication as well as kinase inhibitors and biologics. J Dtsch Dermatol Ges 2022; 20:777.</a></li><li><a class="nounderline abstract_t">Brayer M, Lepage C, Taieb J, Tougeron D. Lichenoid eruption during antiPD-L1 immunotherapy with avelumab in metastatic colorectal cancer. Clin Res Hepatol Gastroenterol 2022; 46:101924.</a></li><li><a class="nounderline abstract_t">Farinazzo E, Ponis G, Zelin E, et al. Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy. J Eur Acad Dermatol Venereol 2021; 35:e548.</a></li><li><a class="nounderline abstract_t">Hiltun I, Sarriugarte J, Martínez-de-Espronceda I, et al. Lichen planus arising after COVID-19 vaccination. J Eur Acad Dermatol Venereol 2021; 35:e414.</a></li><li><a class="nounderline abstract_t">Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide. Dermatol Clin 2021; 39:653.</a></li><li><a class="nounderline abstract_t">Mintoff D, Pisani D, Livori N, et al. SARS-CoV-2 mRNA booster vaccine-associated lichenoid drug eruption. J Eur Acad Dermatol Venereol 2022; 36:e617.</a></li><li><a class="nounderline abstract_t">Merhy R, Sarkis AS, Kaikati J, et al. New-onset cutaneous lichen planus triggered by COVID-19 vaccination. J Eur Acad Dermatol Venereol 2021; 35:e729.</a></li><li><a class="nounderline abstract_t">Alrawashdeh HM, Al-Habahbeh O, Naser AY, et al. Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature. Cureus 2022; 14:e22669.</a></li><li><a class="nounderline abstract_t">Correia C, Fernandes S, Soares-de-Almeida L, Filipe P. Exuberant lichenoid eruption after Oxford-AstraZeneca COVID-19 vaccine: a singular case. J Eur Acad Dermatol Venereol 2022; 36:e268.</a></li><li><a class="nounderline abstract_t">Lai YC, Yew YW. Lichen planus and lichenoid drug eruption after vaccination. Cutis 2017; 100:E6.</a></li><li><a class="nounderline abstract_t">Schmutz JL, Barbaud A, Trechot P. [Drug-induced lichenoid eruptions]. Ann Dermatol Venereol 2006; 133:409.</a></li><li><a class="nounderline abstract_t">Rivarola de Gutierrez E, Abaca H. Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy. Dermatology 2004; 208:232.</a></li><li><a class="nounderline abstract_t">Canonne-Courivaud D, Carpentier O, Dejobert Y, et al. [Lichenoid drug reaction to leflunomide]. Ann Dermatol Venereol 2003; 130:435.</a></li><li><a class="nounderline abstract_t">Agharbi FZ, Aasfara J, Oqbani K, et al. Lichenoid Drug Eruption Induced by Teriflunomide. Ann Indian Acad Neurol 2023; 26:275.</a></li><li><a class="nounderline abstract_t">Kubo Y, Fukumoto D, Ishigami T, et al. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol 2010; 37:807.</a></li><li><a class="nounderline abstract_t">Johnston GA. Thiazide-induced lichenoid photosensitivity. Clin Exp Dermatol 2002; 27:670.</a></li><li><a class="nounderline abstract_t">Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6:431.</a></li><li><a class="nounderline abstract_t">Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25:345.</a></li><li class="breakAll">Bork K. Lichenoid eruptions. In: Cutaneous Side Effects of Drugs, Bork K (Ed), WB Saunders, 1988. p.170.</li><li><a class="nounderline abstract_t">Lehloenya RJ, Phillips EJ, Pasieka HB, Peter J. Recognizing Drug Hypersensitivity in Pigmented Skin. Immunol Allergy Clin North Am 2022; 42:219.</a></li><li><a class="nounderline abstract_t">Anderson TE. Lichen planus following quinidine therapy. Br J Dermatol 1967; 79:500.</a></li><li><a class="nounderline abstract_t">Seehafer JR, Rogers RS 3rd, Fleming CR, Dickson ER. Lichen planus-like lesions caused by penicillamine in primary biliary cirrhosis. Arch Dermatol 1981; 117:140.</a></li><li><a class="nounderline abstract_t">Oliver GF, Winkelmann RK, Muller SA. Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases. J Am Acad Dermatol 1989; 21:284.</a></li><li><a class="nounderline abstract_t">Barbaud A, Gonçalo M, Bruynzeel D, et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:321.</a></li><li><a class="nounderline abstract_t">Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209:209.</a></li><li><a class="nounderline abstract_t">Lomaga MA, Polak S, Grushka M, Walsh S. Results of patch testing in patients diagnosed with oral lichen planus. J Cutan Med Surg 2009; 13:88.</a></li><li><a class="nounderline abstract_t">Braswell DS, Hakeem A, Walker A, et al. Lichenoid granulomatous dermatitis revisited: A retrospective case series. J Am Acad Dermatol 2019; 81:1157.</a></li><li><a class="nounderline abstract_t">Khelifa-Hamdani E, Touati-Serraj M, Perriard J, et al. Giant cell lichenoid dermatitis in a patient with baboon syndrome. J Cutan Pathol 2008; 35 Suppl 1:17.</a></li><li><a class="nounderline abstract_t">Böer A. Keratosis lichenoides chronica: proposal of a concept. Am J Dermatopathol 2006; 28:260.</a></li><li><a class="nounderline abstract_t">Konstantinov KN, Søndergaard J, Izuno G, Obreshkova E. Keratosis lichenoides chronica. J Am Acad Dermatol 1998; 38:306.</a></li><li><a class="nounderline abstract_t">Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol 1998; 16:325.</a></li><li><a class="nounderline abstract_t">Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134:1521.</a></li><li><a class="nounderline abstract_t">Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol 1991; 24:434.</a></li><li><a class="nounderline abstract_t">Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med 2012; 366:723.</a></li><li><a class="nounderline abstract_t">Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012; :CD008092.</a></li><li><a class="nounderline abstract_t">Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011; :CD001168.</a></li><li><a class="nounderline abstract_t">Eldani C, Darrigade AS, Beylot-Barry M, et al. Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like". Eur J Dermatol 2022; 32:805.</a></li></ol></div><div id="topicVersionRevision">Topic 15763 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144288" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16471460" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A case of lichenoid drug eruption associated with sildenafil citratus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19891921" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lichenoid drug eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539844" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242512" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335745" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lichenoid drug eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2146290" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A comparative histopathologic study of photodistributed and nonphotodistributed lichenoid drug eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22416968" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19689525" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oral lichenoid drug eruption: a report of a pediatric case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28543792" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lichenoid Drug Eruption with Prominent Nail Changes Due to Leflunomide in a 12-Year-Old Child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23869619" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Guanfacine-induced lichenoid drug eruption in a child with autism and attention deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16285316" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : [Mechanisms of cutaneous drug reactions].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735949" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Autocytotoxic T-cell clones in lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964704" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Immunohistology of drug-induced exanthema: clues to pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10848903" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112902" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29211335" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lichen planus-like drug eruption on anti-PD-1 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31210413" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18719608" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chemokines in the pathogenesis of lichenoid tissue reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026519" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Type I interferon-associated cytotoxic inflammation in lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657628" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased serum levels of tumor necrosis factor alpha in lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8100122" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17310003" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Yin and Yang of TNF-{alpha} inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652271" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14730245" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Spontaneous tolerance to terbinafine-induced lichenoid drug eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2527767" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650025" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lichenoid drug eruption with proton pump inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18005023" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lichenoid reaction induced by adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225003" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6355216" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Primary biliary cirrhosis and lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2535012" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Drug eruptions with lichenoid histology produced by captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6452466" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27411054" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265627" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27777187" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lichenoid drug eruption caused by adalimumab: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34887290" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Certolizumab-induced lichenoid eruption in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36789996" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Imatinib-induced lichen planus and lichenoid drug eruption: A report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35585029" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lichenoid Drug Eruptions Associated With the Use of Biologic Therapy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36798857" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lichenoid-granulomatous drug reactions to dupilumab: A report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34189218" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : De novo case of lichenoid eruption following dupilumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36250258" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lichenoid eruption during treatment of atopic dermatitis with dupilumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26957557" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26762844" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085692" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35711043" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Epidermal necrolysis in the context of immuno-oncologic medication as well as kinase inhibitors and biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35462061" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lichenoid eruption during antiPD-L1 immunotherapy with avelumab in metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34021625" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33724563" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lichen planus arising after COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556254" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35429052" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : SARS-CoV-2 mRNA booster vaccine-associated lichenoid drug eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34236718" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New-onset cutaneous lichen planus triggered by COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35386174" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34913207" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Exuberant lichenoid eruption after Oxford-AstraZeneca COVID-19 vaccine: a singular case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29360907" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lichen planus and lichenoid drug eruption after vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16733466" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : [Drug-induced lichenoid eruptions].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15118375" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843855" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : [Lichenoid drug reaction to leflunomide].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37538413" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lichenoid Drug Eruption Induced by Teriflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883365" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472543" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Thiazide-induced lichenoid photosensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17688387" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Drug-induced photoallergic and phototoxic reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020173" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020173" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35469616" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recognizing Drug Hypersensitivity in Pigmented Skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6039636" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lichen planus following quinidine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6452095" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lichen planus-like lesions caused by penicillamine in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2768578" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11846746" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767038" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Drug patch testing in systemic cutaneous drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19298777" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Results of patch testing in patients diagnosed with oral lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31378565" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Lichenoid granulomatous dermatitis revisited: A retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544061" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Giant cell lichenoid dermatitis in a patient with baboon syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778533" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Keratosis lichenoides chronica: proposal of a concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486703" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Keratosis lichenoides chronica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9642527" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Drug-induced lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875189" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of lichen planus. An evidence-based medicine analysis of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1829465" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22356325" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical practice. Lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336835" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Interventions for erosive lichen planus affecting mucosal sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21735381" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Interventions for treating oral lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36856394" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
